olanzapine

P3, N=200, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227

This review highlights that, despite the absence of pharmacological agents specifically approved for CAC in the United States and Europe, current guidelines recommend multimodal supportive care, including low-dose olanzapine, nutritional support, and exercise-based interventions. Furthermore, we identify recent phase 2 trials targeting the GDF-15 pathway, such as the GDF-15 inhibitor ponsegromab, which have demonstrated significant improvements in body weight and physical activity, suggesting a potential breakthrough in targeted therapies for CAC...It manifests as a lethal systemic pathology that demands early identification and targeted personalized pharmacological and nutritional interventions. Early diagnosis and targeted intervention represent promising strategies for improving survival and quality of life in this high-risk patient population.

P3, N=348, Completed, Murdoch Children's Research Institute (MCRI) | Recruiting --> Completed

P3, N=644, Completed, Fudan University | Not yet recruiting --> Completed | Trial completion date: May 2026 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025

P2, N=200, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting

P2, N=24, Completed, The University of Technology Sydney | Recruiting --> Completed

P4, N=200, Not yet recruiting, Shanghai 6th People's Hospital

Conversely, compared with those of the model group, the expression of NPY, SOCS3, NLRP3, ASC, cleaved caspase-1, GSDMD-N, and IL-1β was significantly downregulated, and the expression of POMC and LEPR was significantly upregulated in the medium-and high-dose HLWDD groups and the metformin group. These results collectively indicate that HLWDD ameliorates olanzapine-induced feeding dysregulation by mitigating leptin resistance through suppression of NLRP3-driven neuroinflammatory pathways in the arcuate nucleus.

P2, N=200, Not yet recruiting, Chinese University of Hong Kong

P3, N=222, Recruiting, Affiliated Hospital of Qinghai University | Initiation date: Sep 2025 --> Feb 2026

P=N/A, N=238, Not yet recruiting, Henan Cancer Hospital